ORIC PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
ORIC PHARMACEUTICALS, INC. (ORIC) reported Proceeds from Sale and Maturity of Marketable Securities of $120.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $60.00M, a 26.32% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $60.00M, a 31.43% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $62.50M, a 19.35% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $55.00M, a 29.03% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $252.50M, a 8.26% decline from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $275.25M, a 39.94% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $196.69M, a 50.20% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $130.95M, a 42.81% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $120.00M 10-Q · filed 2026-08-03 | $182.50M derived: sum of 3 quarters · filed 2026-08-03 | $237.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $60.00M 10-Q · filed 2026-05-04 | $122.50M derived: sum of 2 quarters · filed 2026-05-04 | $177.50M derived: sum of 3 quarters · filed 2026-05-04 | $225.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $62.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $117.50M derived: sum of 2 quarters · filed 2026-02-23 | $165.00M derived: sum of 3 quarters · filed 2026-08-03 | $252.50M 10-K · filed 2026-02-23 |
| 2025-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $102.50M derived: sum of 2 quarters · filed 2026-08-03 | $190.00M 10-Q · filed 2025-11-13 | $267.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $47.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $135.00M 10-Q · filed 2026-08-03 | $212.50M derived: sum of 3 quarters · filed 2026-08-03 | $290.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $87.50M 10-Q · filed 2026-05-04 | $165.00M derived: sum of 2 quarters · filed 2026-05-04 | $242.50M derived: sum of 3 quarters · filed 2026-05-04 | $310.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $77.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $155.00M derived: sum of 2 quarters · filed 2026-02-23 | $222.50M derived: sum of 3 quarters · filed 2026-02-23 | $275.25M 10-K · filed 2026-02-23 |
| 2024-09-30 | $77.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $145.00M derived: sum of 2 quarters · filed 2025-11-13 | $197.75M 10-Q · filed 2025-11-13 | $247.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $67.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $120.25M 10-Q · filed 2025-08-12 | $170.24M derived: sum of 3 quarters · filed 2025-08-12 | $223.47M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $52.74M 10-Q · filed 2025-05-05 | $102.73M derived: sum of 2 quarters · filed 2025-05-05 | $155.97M derived: sum of 3 quarters · filed 2025-05-05 | $192.96M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $49.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $103.22M derived: sum of 2 quarters · filed 2025-02-18 | $140.22M derived: sum of 3 quarters · filed 2025-02-18 | $196.69M 10-K · filed 2025-02-18 |
| 2023-09-30 | $53.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $90.22M derived: sum of 2 quarters · filed 2024-11-12 | $146.70M 10-Q · filed 2024-11-12 | $206.92M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $36.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $93.47M 10-Q · filed 2024-08-12 | $153.68M derived: sum of 3 quarters · filed 2024-08-12 | $214.42M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $56.48M 10-Q · filed 2024-05-06 | $116.69M derived: sum of 2 quarters · filed 2024-05-06 | $177.43M derived: sum of 3 quarters · filed 2024-05-06 | $177.43M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $60.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $120.95M derived: sum of 2 quarters · filed 2024-03-11 | $120.95M derived: sum of 3 quarters · filed 2024-03-11 | $130.95M 10-K · filed 2024-03-11 |
| 2022-09-30 | $60.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $60.73M derived: sum of 2 quarters · filed 2023-11-06 | $70.73M 10-Q · filed 2023-11-06 | $108.23M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $10.00M 10-Q · filed 2023-08-10 | $47.50M derived: sum of 3 quarters · filed 2023-08-10 | $90.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $10.00M 10-Q · filed 2023-05-08 | $47.50M derived: sum of 2 quarters · filed 2023-05-08 | $90.50M derived: sum of 3 quarters · filed 2023-05-08 | $173.00M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $37.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $80.50M derived: sum of 2 quarters · filed 2023-03-16 | $163.00M derived: sum of 3 quarters · filed 2023-03-16 | $229.00M 10-K · filed 2023-03-16 |
| 2021-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $125.50M derived: sum of 2 quarters · filed 2022-11-07 | $191.50M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $82.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $148.50M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $66.00M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $10.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |